{"disease":{"id":"malignant-lymphoma","name":"Malignant lymphoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"ibrutinib","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imbruvica","generic_name":"ibrutinib","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Blk","drug_class":"Kinase Inhibitor [EPC]","quality_score":74,"revenue":"3200","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells."},{"drug_id":"venetoclax","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venclexta","generic_name":"venetoclax","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"BCL-2 Inhibitor [EPC]","quality_score":80,"revenue":"2583","mechanism":"Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein."},{"drug_id":"cyclophosphamide","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"brentuximab-vedotin","indication_name":"Anaplastic large T-cell systemic malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adcetris","generic_name":"brentuximab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"CD30-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"900","mechanism":"Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells."},{"drug_id":"tafasitamab","indication_name":"Malignant lymphoma, large B-cell, diffuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xmab5574","generic_name":"tafasitamab","company_name":"Morphosys Us Inc","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD19","drug_class":"","quality_score":null,"revenue":"100","mechanism":"Tafasitamab works by binding to the CD19 antigen on B-lymphocytes, triggering an immune response against cancer cells."},{"drug_id":"busilvex","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"imbruvica","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imbruvica","company_name":"Rabin Medical Center","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mozobil","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mozobil","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"busulfan","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"chembl-chembl1200796","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"duvelisib","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Copiktra","generic_name":"DUVELISIB","company_name":"Secura","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Copiktra works by blocking an enzyme that helps cancer cells grow and multiply."},{"drug_id":"busulfex","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Non-Hodgkin's malignant lymphomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"zydelig","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zydelig","company_name":"University of Maryland, Baltimore","drug_phase":"marketed","molecular_target":"DNA-dependent protein kinase catalytic subunit, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"plerixafor","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mozobil","generic_name":"plerixafor","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 2","drug_class":"Hematopoietic Stem Cell Mobilizer [EPC]","quality_score":61,"revenue":null,"mechanism":"Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream."},{"drug_id":"brentuximab","indication_name":"Anaplastic large T-cell systemic malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brentuximab","company_name":"University of Arizona","drug_phase":"discontinued","molecular_target":"Tumor necrosis factor receptor superfamily member 8, Tubulin beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cyclophosphamid","indication_name":"Malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tafasitamab-cxix","indication_name":"Malignant lymphoma, large B-cell, diffuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MONJUVI","generic_name":"TAFASITAMAB-CXIX","company_name":"MORPHOSYS US INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD19","drug_class":"","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06153576","title":"The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures","phase":"","overall_status":"COMPLETED","enrollment_count":1120,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT05190263","title":"Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":1053,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT03469921","title":"Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016","phase":"","overall_status":"COMPLETED","enrollment_count":602,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT04593277","title":"Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT05510908","title":"Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC","phase":"","overall_status":"COMPLETED","enrollment_count":460,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":true},{"nct_id":"NCT03222258","title":"Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07259304","title":"Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05663502","title":"Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":false},{"nct_id":"NCT04090619","title":"Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":192,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06358001","title":"EchoTip AcuCore Post-Market Clinical Study","phase":"","overall_status":"COMPLETED","enrollment_count":183,"lead_sponsor_name":"Cook Research Incorporated","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05545202","title":"A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Pharmacosmos A/S","has_results":false},{"nct_id":"NCT06475820","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04698616","title":"Lean Body Mass and Side Effects in Patients With Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":141,"lead_sponsor_name":"Jens Rikardt Andersen","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00939770","title":"Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT05827341","title":"A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials","phase":"","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04464590","title":"Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03315520","title":"BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","has_results":false},{"nct_id":"NCT02732275","title":"DS-3201b in Participants With Lymphomas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":false},{"nct_id":"NCT06223542","title":"Studying TAK-243 in Patients With Advanced Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":95,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02408861","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04477772","title":"A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT04439175","title":"Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02978625","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05857969","title":"Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"Florida International University","has_results":false},{"nct_id":"NCT02646098","title":"CD34+ Selected ASCT for Aggressive Lymphomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT05007652","title":"A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT04870944","title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT05293990","title":"Usefulness of Gadovist-enhanced FLAIR Imaging","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Ryoo, In Seon","has_results":false},{"nct_id":"NCT02323880","title":"Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT02595866","title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05515029","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT04439344","title":"Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04439240","title":"Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06756152","title":"Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT03346096","title":"TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT04439318","title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06390865","title":"Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03205176","title":"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04439214","title":"Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06357975","title":"Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":44,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06390839","title":"Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}